Retrophin (RTRX) Tops Q3 EPS Views

Retrophin (NASDAQ: RTRX) reported Q3 EPS of $0.15, $0.40 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $40.3 million versus the consensus estimate of $40.51 million.

• -- The Phase 3 FORT Study of fosmetpantotenate in pantothenate kinase- associated neurodegeneration (PKAN) remains on-track to complete enrollment in the second half of 2018
• -- The Company received regulatory feedback on its Phase 3 protocol for sparsentan in FSGS; additional statistical analyses to be provided while trial start-up activities continue
• -- Net product sales for the third quarter of 2017 were $40.3 million, compared to $33.9 million for the same period in 2016
• -- Cash, cash equivalents and marketable securities, as of September 30, 2017, totaled $303.9 million
  

For earnings history and earnings-related data on Retrophin (RTRX) click here.

You May Also Be Interested In

• Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
• University Bancorp acquires remaining 20% of UIF for $15.2M
• Red River Bancshares, Inc. (RRBI) Tops Q3 EPS by 7c